QURE
USDuniQure N.V. Ordinary Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$30.810
Kõrge
$32.490
Madal
$28.500
Maht
8.90M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
1.9B
Tööstusharu
Biotehnoloogia
Riik
Netherlands
Kauplemisstatistika
Keskmine maht
3.75M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). The investigation concerns whether the
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
Goldman Sachs analyst Salveen Richter maintains uniQure with a Neutral and lowers the price target from $56 to $38.
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
RBC Capital analyst Luca Issi maintains uniQure with a Outperform and lowers the price target from $65 to $45.
William Blair Downgrades uniQure to Market Perform
William Blair analyst Sami Corwin downgrades uniQure from Outperform to Market Perform.
HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70
HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure with a Buy and lowers the price target from $110 to $70.
Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53
Chardan Capital analyst Daniil Gataulin maintains uniQure with a Buy and lowers the price target from $76 to $53.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.